Onward Medical N.V. (EBR:ONWD)
Belgium · Delayed Price · Currency is EUR | Market Cap | 161.65M -13.7% |
| Revenue (ttm) | 5.41M +211.3% |
| Net Income | -41.79M |
| EPS | -0.90 |
| Shares Out | 69.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 76,516 |
| Open | 2.350 |
| Previous Close | 2.325 |
| Day's Range | 2.310 - 2.405 |
| 52-Week Range | 2.270 - 5.770 |
| Beta | 0.85 |
| Analysts | Strong Buy |
| Price Target | 9.24 (+284.2%) |
| Earnings Date | Sep 2, 2026 |
About Onward Medical
Onward Medical N.V., a medical technology company, develops and commercializes therapies to enable functional recovery for people with spinal cord injury (SCI) in the United States, Europe, and internationally. The company offers ARCEX System, an external stimulator that is intended to improve hand strength and sensation following SCI; ARCIM System, an implantable system currently used to explore potential indications in clinical feasibility studies; ARCBCI System, an implantable system currently being investigated to enable thought driven move... [Read more]
Financial Performance
In 2025, Onward Medical's revenue was 5.41 million, an increase of 211.33% compared to the previous year's 1.74 million. Losses were -41.79 million, 17.0% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for ONWD stock is "Strong Buy." The 12-month stock price target is €9.24, which is an increase of 284.20% from the latest price.
News
Onward Medical Slides: Corporate presentation
Onward Medical has posted slides in relation to its latest quarterly earnings report, which was published on July 1, 2026.
Onward Medical Earnings Call Transcript: Q1 2026
Q1 revenue reached EUR 2 million, driven by strong ARC-EX adoption in clinics and homes, with home units surpassing clinic units for the first time. A EUR 40 million equity raise extended the cash runway into Q1 2028, while clinical and commercial expansion continues in the U.S. and Europe.
Onward Medical Earnings release: Q1 2026
Onward Medical released its Q1 2026 earnings on May 26, 2026, summarizing the period's financial results.
Onward Medical Slides: Q1 2026
Onward Medical has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 26, 2026.
ONWARD Medical Reports First Quarter 2026 Results with Strong Commercial Momentum and Key Clinical Milestones
EINDHOVEN, the Netherlands, May 26, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, functio...
ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026
EINDHOVEN, The Netherlands, May 19, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, functio...
ONWARD Medical Publishes Closing of Bookbuild Offering
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)
ONWARD Medical Successfully Raises over EUR 40 Million in Capital Increase
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHE...
ONWARD Medical Launches Capital Increase for Indicative Amount of EUR 40 Million
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHE...
ONWARD Medical Publishes Convocation of the 2026 Annual General Meeting of Shareholders and Proposed Resolutions
EINDHOVEN, the Netherlands, April 01, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, funct...
Onward Medical Earnings Call Transcript: H2 2025
Achieved rapid U.S. market penetration with 117 ARC-EX systems sold, EUR 5.4M in revenue, and major regulatory milestones. Raised over EUR 50M, advanced pivotal studies, and set the stage for accelerated growth and potential Nasdaq IPO.
Onward Medical Annual report: H2 2025
Onward Medical has published its H2 2025 annual report on March 31, 2026.
Onward Medical Earnings release: H2 2025
Onward Medical released its H2 2025 earnings on March 31, 2026, summarizing the period's financial results.
Onward Medical Slides: H2 2025
Onward Medical has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 31, 2026.
ONWARD Medical Reports Full Year 2025 Financial and Operating Results, Highlighting Strong US Commercial Performance and Major Pipeline Milestones
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)
ONWARD Medical Schedules Webcast to Report Full-Year 2025 Financial Results and Provide Business Update
EINDHOVEN, the Netherlands, March 23, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, funct...
ONWARD Medical Announces First Participant Enrolled in Global Pivotal Study Evaluating ARC-IM System to Address Blood Pressure Instability After Spinal Cord Injury
EINDHOVEN, the Netherlands, Feb. 04, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the neurotechnology company pioneering spinal cord stimulation therapies to rest...
ONWARD Medical Completes Two Additional Brain-Computer Interface Implants Paired with Spinal Cord Stimulation Technology to Restore Thought-Driven Movement
EINDHOVEN, the Netherlands, Jan. 22, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the neurotechnology company pioneering spinal cord stimulation therapies to restore ...
Onward Medical Transcript: Life Sciences Virtual Investor Forum 2025
Innovative spinal cord stimulation platforms are advancing through commercialization and clinical trials, with strong early sales, robust clinical evidence, and strategic funding. Key milestones include expanding sales, pivotal trial progress, and new device launches in the next year.
Onward Medical Earnings Call Transcript: Q3 2025
Q3 revenue reached EUR 1.7 million with strong U.S. clinic adoption and high device utilization. Regulatory milestones and a EUR 50 million capital raise support European and home use expansion, with robust demand and a solid cash position.
Onward Medical Earnings release: Q3 2025
Onward Medical released its Q3 2025 earnings on November 24, 2025, summarizing the period's financial results.
Onward Medical Slides: Q3 2025
Onward Medical has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 24, 2025.
ONWARD Medical Drives Strong US ARC-EX Adoption and Achieves Important Scientific and Regulatory Milestones in Q3 2025
EINDHOVEN, the Netherlands, Nov. 24, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, functi...
ONWARD Medical Receives FDA 510(k) Clearance Expanding ARC-EX System Indication for Home Use
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)
ONWARD Medical Successfully Raises Over EUR 50 Million in Capital Increase
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHE...